Wells Fargo & Company Relmada Therapeutics, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 350 shares of RLMD stock, worth $1,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares

350

Previous 543 35.54%

Holding current value

$1,081

Previous $2,000 50.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.93 - $4.94 $565 - $953	-193 Reduced 35.54%	350 $1,000
Q1 2024 May 10, 2024	BUY	$3.1 - $6.8 $9 - $20	3 Added 0.56%	543 $2,000
Q4 2023 Feb 09, 2024	BUY	$2.45 - $4.22 $24 - $42	10 Added 1.89%	540 $2,000
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.79 $9 - $15	-4 Reduced 0.75%	530 $1,000
Q2 2023 Aug 15, 2023	SELL	$2.22 - $3.54 $10,724 - $17,101	-4,831 Reduced 90.05%	534 $1,000
Q1 2023 May 12, 2023	BUY	$2.24 - $4.76 $9,457 - $20,096	4,222 Added 369.38%	5,365 $12,000
Q4 2022 Feb 13, 2023	SELL	$2.17 - $35.84 $44,940 - $742,246	-20,710 Reduced 94.77%	1,143 $3,000
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $58,175 - $117,686	-3,179 Reduced 12.7%	21,853 $809,000
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $13,233 - $24,332	802 Added 3.31%	25,032 $476,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $264,861 - $427,548	15,841 Added 188.83%	24,230 $654,000
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $120,473 - $190,851	7,116 Added 558.99%	8,389 $189,000
Q3 2021 Nov 15, 2021	SELL	$21.86 - $34.77 $180,825 - $287,617	-8,272 Reduced 86.66%	1,273 $33,000
Q2 2021 Aug 16, 2021	SELL	$29.55 - $39.15 $81,764 - $108,328	-2,767 Reduced 22.47%	9,545 $306,000
Q1 2021 May 13, 2021	SELL	$31.52 - $39.28 $971,509 - $1.21 Million	-30,822 Reduced 71.46%	12,312 $434,000
Q4 2020 Feb 09, 2021	BUY	$29.88 - $39.8 $244,687 - $325,922	8,189 Added 23.43%	43,134 $1.38 Million
Q3 2020 Nov 05, 2020	SELL	$34.42 - $43.78 $138,127 - $175,689	-4,013 Reduced 10.3%	34,945 $1.31 Million
Q2 2020 Aug 13, 2020	BUY	$31.59 - $49.98 $861,554 - $1.36 Million	27,273 Added 233.4%	38,958 $1.74 Million
Q1 2020 May 14, 2020	BUY	$23.78 - $50.12 $277,869 - $585,652	11,685 New	11,685 $399,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

13.5M

Call Options Held

85.8K

Put Options Held

42.8K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $88.4M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Relmada Therapeutics, Inc. Transaction History